Curaleaf Q3 2026 revenue $352.7M, up 10.9%; net loss $37.4M; adjusted EBITDA $77.6M

Curaleaf Holdings, Inc.

Net revenue $352.7M vs $317.9M in Q3 2025 (+10.9%); sequentially up 3.6% from $340.1M. International revenue $59M (+28%), domestic +8%.
Net loss attributable to Curaleaf from continuing operations $37.4M, or $0.14 per share; adjusted EBITDA $77.6M at 22.0% margin, down 56 bps YoY.
Adjusted gross margin 48.7% (-186 bps YoY); gross profit $170.5M at 48.3% margin. Cash and equivalents $104.9M; Q3 operating cash flow $22M, targeting ~$150M for the year.
Nine-month revenue $1,017.0M (+9% YoY) and net income of $45.2M ($0.17/share); retired/repurchased 1.12M shares for $8.4M year-to-date.
Opened two Florida dispensaries (Port Richey, Riverview) bringing total to 188; added to FTSE Canada All Cap Index; commenced offer to buy all Aurora Cannabis shares for SVS plus cash.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.